• Home
  • News
  • Coins2Day 500
    • Coins2Day Global 500
    • Coins2Day 500 Europe
    • Coins2Day China 500
    • Coins2Day SEA 500
    • Great Place To Work
  • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Investing
    • Banking
    • Crypto
  • Leadership
    • Success
    • Future Of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Analytics
  • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Home
  • News
  • Coins2Day 500
    • Coins2Day 500
    • Coins2Day Global 500
    • Coins2Day 500 Europe
    • Coins2Day China 500
    • Coins2Day SEA 500
    • Great Place To Work
  • Tech
    • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Investing
    • Banking
    • Crypto
  • Leadership
    • Leadership
    • Success
    • Future Of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Rankings
    • Analytics
  • Multimedia
    • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Asia
  • Europe
  • Analytics
  1. home
  1. home
  2. Allergan

Allergan

Page 6 of 6

Is Valeant the wrong partner for Bill Ackman’s bid for Allergan?

Is Valeant the wrong partner for Bill Ackman’s bid for Allergan?

By News Correspondent
October 30, 2014
Botox
Finance

SEC is reportedly probing the Valeant-Ackman bid for Botox-maker Allergan

By Crypto Correspondent
August 14, 2014
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
Finance

Bill Ackman confirms Pershing Square Holdings IPO plan

By Research Team
August 13, 2014
Invest Todd Ahlsten
Finance

Riding high, with one eye on the ‘What If?’

By Editorial Team
July 7, 2014
Morgan Stanley caught playing both sides of Allergan-Valeant fight
Finance

Morgan Stanley caught playing both sides of Allergan-Valeant fight

By Senior Editor
June 16, 2014
Botox Treatment
Finance

Allergan and Valeant are both hypocrites

By Investment Desk
June 2, 2014
Valeant Offers to Buy Allergan With Pershing's Support
Finance

Valeant injects more cash into bid for Botox-maker Allergan

By Financial Writer
May 30, 2014
Coins2Day
Finance

Valeant boosts bid to buy Botox-maker Allergan

By Staff Writer
May 28, 2014
Coins2Day

Valeant ready to beef up bid for maker of Botox

By Senior Editor
May 13, 2014
Coins2Day
Finance

Allergan rejects Valeant’s $46 billion takeover bid

By Investment Desk
May 12, 2014

Most Popular

  • AI
    Elon Musk says that in 10 to 20 years, work will be optional and money will be irrelevant thanks to AI and robotics
    By Editorial Team
  • Economy
    One of the world’s most popular economists on why AI is ‘undoubtedly going to crash’: It’s built off ‘digital...
    By Research Team
  • Big Tech
    Nvidia CEO says the company is in a no-win situation amid AI-bubble chatter, leaked meeting reveals
    By News Correspondent
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • MPW
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms of Use
  • Single Issues for Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work at Coins2Day
  • Diversity and Inclusion
  • Terms and Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.